IMQUEST LICENSES ANTI-HIV CANDIDATES

ImQuest Pharmaceuticals has licensed a series of anti-HIV compounds discovered by Korea's Samjin Pharmaceutical. ImQuest plans to develop the lead inhibitor in this series, IQP-0410, as a front-line therapy for HIV infection. The drug class, called pyrimidinediones, consists of unique compounds that possess two highly effective mechanisms of action against HIV; inhibition of reverse transcriptase (RT), and inhibition of virus entry into target cells.

INS News (http://feed.insnews.org/v-cgi/feeds.cgi?feedid=150&story_id=1648919)